Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor. | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor.

Cancer Res (2009) 69 (2_Supplement): 6135.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

J. Randolph Hecht
Madhavan Pillai
Russell Gollard
William Heim
Forrest Swan
Ravi Patel
Lyndah Dreiling
May Mo
Imtiaz Malik

Clinical Colorectal Cancer (2010) 9 (2): 95.